AC Immune SA (ACIU)Healthcare | Biotechnology | Lausanne, Switzerland | NasdaqGM
2.39 USD
-0.06
(-2.449%) ⇩
(Oct. 16, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 6:56 a.m. EDT
The recent rally in AC Immune is driven entirely by speculative catalysts—the amended collaboration deal with Lilly and upcoming conference presentations—rather than a fundamental turnaround. While the company shows positive revenue growth and a forward P/E suggests potential profitability, the underlying business remains deeply distressed with negative gross margins and massive free cash burn. The market has punished this stock severely over the last decade, dropping nearly 77% over the trailing nine-year window, and the options chain confirms that traders are betting against a continuation of this decline. With no dividend to cushion the blow and a balance sheet showing significant cash burn, the risk-reward profile remains skewed toward caution until the pipeline delivers definitive clinical proof of concept. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.050929 |
| AutoTheta | 0.050930 |
| AutoARIMA | 0.051485 |
| MSTL | 0.052194 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 0.41 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.649 |
| Excess Kurtosis | -0.66 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 11.664 |
| Revenue per Share | 0.173 |
| Market Cap | 237,630,368 |
| Forward P/E | 3.99 |
| Beta | 1.55 |
| Profit Margins | -246.48% |
| Website | https://www.acimmune.com |
As of Oct. 10, 2026, 6:56 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest significantly exceeds call open interest across all expirations, with deep out-of-the-money puts holding substantial volume relative to calls. This indicates a market consensus expecting further volatility or a drop in price, despite the recent rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.18983048 |
| Address1 | Building B |
| Address2 | EPFL Innovation Park |
| All Time High | 19.97 |
| All Time Low | 1.43 |
| Ask | 2.9 |
| Ask Size | 1 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 189,430 |
| Average Daily Volume3 Month | 198,176 |
| Average Volume | 198,176 |
| Average Volume10Days | 189,430 |
| Beta | 1.553 |
| Bid | 1.6 |
| Bid Size | 2 |
| Book Value | 0.4276037 |
| City | Lausanne |
| Country | Switzerland |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.39 |
| Current Ratio | 0.932 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 2.47 |
| Day Low | 2.385 |
| Debt To Equity | 11.664 |
| Display Name | AC Immune |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,785,933,000 |
| Earnings Timestamp End | 1,793,795,400 |
| Earnings Timestamp Start | 1,793,795,400 |
| Ebitda | -42,479,000 |
| Ebitda Margins | -2.42612 |
| Enterprise To Ebitda | -3.917 |
| Enterprise To Revenue | 9.502 |
| Enterprise Value | 166,375,360 |
| Eps Current Year | -0.415 |
| Eps Forward | 0.5987297 |
| Eps Trailing Twelve Months | -0.54 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 41 21 345 91 20 |
| Fifty Day Average | 2.6402 |
| Fifty Day Average Change | -0.2501998 |
| Fifty Day Average Change Percent | -0.09476548 |
| Fifty Two Week Change Percent | -18.983047 |
| Fifty Two Week High | 4.0 |
| Fifty Two Week High Change | -1.6099999 |
| Fifty Two Week High Change Percent | -0.40249997 |
| Fifty Two Week Low | 2.095 |
| Fifty Two Week Low Change | 0.29500008 |
| Fifty Two Week Low Change Percent | 0.14081149 |
| Fifty Two Week Range | 2.095 - 4.0 |
| Financial Currency | CHF |
| First Trade Date Milliseconds | 1,474,637,400,000 |
| Float Shares | 39,181,171 |
| Forward Eps | 0.5987297 |
| Forward P E | 3.9917846 |
| Free Cashflow | -33,138,624 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 90 |
| Fullday Change | -0.059999943 |
| Fullday Change Percent | -2.4489772 |
| Fullday Price | 2.39 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -1.62231 |
| Gross Profits | -28,405,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.38094002 |
| Held Percent Institutions | 0.24334998 |
| Implied Shares Outstanding | 99,426,932 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland. |
| Long Name | AC Immune SA |
| Market | us_market |
| Market Cap | 237,630,368 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_22309440 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -43,156,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 281,378,217 |
| Number Of Analyst Opinions | 4 |
| Open | 2.45 |
| Operating Cashflow | -50,494,000 |
| Operating Margins | 0.078940004 |
| Payout Ratio | 0.0 |
| Phone | 41 21 345 91 21 |
| Previous Close | 2.45 |
| Price Eps Current Year | -5.7590365 |
| Price Hint | 4 |
| Price To Book | 5.5892878 |
| Price To Sales Trailing12 Months | 13.571898 |
| Profit Margins | -2.46479 |
| Quick Ratio | 0.888 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.0599999 |
| Regular Market Change Percent | -2.44898 |
| Regular Market Day High | 2.47 |
| Regular Market Day Low | 2.385 |
| Regular Market Day Range | 2.385 - 2.47 |
| Regular Market Open | 2.45 |
| Regular Market Previous Close | 2.45 |
| Regular Market Price | 2.39 |
| Regular Market Time | 1,792,180,801 |
| Regular Market Volume | 126,849 |
| Return On Assets | -0.16036 |
| Return On Equity | -0.78528 |
| Revenue Growth | 10.572 |
| Revenue Per Share | 0.173 |
| Sand P52 Week Change | 0.13723719 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 99,426,932 |
| Shares Percent Shares Out | 0.0354 |
| Shares Short | 3,524,624 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 3,296,131 |
| Short Name | AC Immune SA |
| Short Percent Of Float | 0.0759 |
| Short Ratio | 21.42 |
| Source Interval | 15 |
| Symbol | ACIU |
| Target High Price | 12.020251 |
| Target Low Price | 5.4091134 |
| Target Mean Price | 8.636672 |
| Target Median Price | 8.558662 |
| Total Cash | 75,357,000 |
| Total Cash Per Share | 0.758 |
| Total Debt | 4,102,000 |
| Total Revenue | 17,509,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.54 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.781325 |
| Two Hundred Day Average Change | -0.391325 |
| Two Hundred Day Average Change Percent | -0.14069733 |
| Type Disp | Equity |
| Volume | 126,849 |
| Website | https://www.acimmune.com |
| Zip | 1,015 |